CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC

May 29-31, 2020; Online at meetings.asco.org/am
Updated analysis finds durvalumab + EP maintains significant OS improvement vs EP alone with no further benefit with addition of tremelimumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Pharma
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Video featuring European experts on immune checkpoint inhibitors for treating early-stage through metastatic hepatocellular carcinoma, from CCO

Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 26, 2020 Expired: October 25, 2021

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD review the role of IO therapy and CRT for early stage NSCLC.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Gain key clinical insights fast, with this short slideset from CCO on new biomarkers driving precision care in lung cancer

Edward S. Kim, MD, FACP Sandip P. Patel, MD Released: October 23, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD provides insights on the latest data on IO therapy for lung cancer.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue